Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224892

Enrollment

240

Registered

2019-09-27

Start date

2019-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

investigational material(s) Generic name etc : PF-06700841 INN of investigational material : - Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: *Participants with a diagnosis of plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Day 1. *Participants with a Physician Global Assessment (PGA) score of mild (2) or moderate (3) at Screening and Day 1. *At Screening and Day 1, have plaque psoriasis covering 2%-15% (inclusive) of total body surface area (BSA) on the trunk and/or limbs.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: *other skin conditions that would interfere with the evaluation of psoriasis *history of herpes zoster or simplex *Infected with Mycobacterium tuberculosis

Design outcomes

Primary

Measure	Time frame
efficacy Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12	—

Secondary

Measure	Time frame
safety efficacy Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 Change From Baseline in PASI Scores at Week 14 and 16 Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 Percent Change From Baseline in PASI Scores at Week 14 and 16 Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 Absolute PP-NRS Score at Week 14 and 16 Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 Change From Baseline in PP-NRS Score at Week 14 and 16 Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs Number of Participants With TEAEs by Severity Number of Participants Who Discontinued From Study Due to Adverse Events Number of Participants With Laboratory Abnormalities Meeting Specified Criteria Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data *Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Da	—

Measure

Time frame

safety efficacy *Percentage of Participants With Physician Global Assessment (PGA) Score Clear (0) or Almost Clear (1) and Greater Than or Equal to (>=) 2 Points Improvement From Baseline at Week 12 *Percentage of Participants With 75% Reduction From Baseline in PASI at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 *Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 *Change From Baseline in PASI Scores at Week 14 and 16 *Percent Change From Baseline in PASI Scores at Week 1, 2, 4, 6, 8, 10 and 12 *Percent Change From Baseline in PASI Scores at Week 14 and 16 *Absolute Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Baseline, Week 1, 2, 4, 6, 8, 10 and 12 *Absolute PP-NRS Score at Week 14 and 16 *Change From Baseline in PP-NRS Score at Week 1, 2, 4, 6, 8, 10 and 12 *Change From Baseline in PP-NRS Score at Week 14 and 16 *Absolute Psoriasis Symptom Inventory (PSI) Score at Baseline, Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, Early Termination (ET), ET Follow-up Visit 1 and 2 *Change From Baseline in PSI Score at Week 1, 2, 4, 6, 8, 10, 12, 14 and 16, ET, ET Follow-up Visit 1 and 2 *Percentage of Participants With PGA Score Clear (0) or Almost Clear (1) and >=2 Points Improvement From Baseline at Week 1, 2, 4, 6, 8, 10, 14, and 16 *Percentage of Participants Who Achieved PSI Score of 0 (Not at All) or 1 (Mild) on All Items at Week 1, 2, 4, 6, 8, 10, 12, 14, and 16 *Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment Related AEs and SAEs *Number of Participants With TEAEs by Severity *Number of Participants Who Discontinued From Study Due to Adverse Events *Number of Participants With Laboratory Abnormalities Meeting Specified Criteria *Number of Participants With Categorical Summary of Post-Baseline Electrocardiogram (ECG) Data *Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data *Number of Participants Classified Per Skin Tolerability Assessment Severity Grades on Da

—

Countries

Europe, Japan, North America, Oceania

Contacts

Public ContactClinical Trials Information Desk

Pfizer R&D Japan G.K.

clinical-trials@pfizer.com+81-3-5309-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026